Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02333370
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- Centre Francois Baclesse
- Target Recruit Count
- 8
- Registration Number
- NCT02322853
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Centre Jean Perrin, Clermont -Ferrand, France
🇫🇷Centre Henri Becquerel, Rouen, France
Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT02291913
- Locations
- 🇺🇸
Woodlands Medical Specialists, Pensacola, Florida, United States
🇺🇸Hope Cancer Center, Terre Haute, Indiana, United States
🇺🇸Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 189
- Registration Number
- NCT02285179
- Locations
- 🇳🇱
Reinier de Graaf Gasthuis, Delft, Netherlands
🇳🇱Haaglanden Medisch Centrum, Den Haag, Netherlands
🇫🇷Gustave Roussy, Paris, France
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 672
- Registration Number
- NCT02278120
- Locations
- 🇺🇸
Penn State University Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Danbury Hospital SC, Danbury, Connecticut, United States
🇺🇸University Of California Los Angeles Dept of Onc, Los Angeles, California, United States
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- GOG Foundation
- Target Recruit Count
- 74
- Registration Number
- NCT02228681
- Locations
- 🇺🇸
Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Women's Cancer Center of Nevada, Las Vegas, Nevada, United States
Endocrine Response in Women With Invasive Lobular Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Priscilla McAuliffe
- Target Recruit Count
- 201
- Registration Number
- NCT02206984
- Locations
- 🇺🇸
Univ. of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸ALBERT EINSTEIN COLLEGE OF MEDICINE Montefiore Medical Center, Bronx, New York, United States
🇺🇸Josh Plassmeyer, Pittsburgh, Pennsylvania, United States
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT02097459
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 79
- Registration Number
- NCT02093351
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Tamoxifen to Treat Barrett's Metaplasia
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT02089386
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.